Abstract

Inactivation of APC is a strongly predisposing event in the development of colorectal cancer1,2, prompting the search for vulnerabilities specific to cells that have lost APC function. Signalling through the mTOR pathway is known to be required for epithelial cell proliferation and tumour growth3,4,5, and the current paradigm suggests that a critical function of mTOR activity is to upregulate translational initiation through phosphorylation of 4EBP1 (refs 6, 7). This model predicts that the mTOR inhibitor rapamycin, which does not efficiently inhibit 4EBP1 (ref. 8), would be ineffective in limiting cancer progression in APC-deficient lesions. Here we show in mice that mTOR complex 1 (mTORC1) activity is absolutely required for the proliferation of Apc-deficient (but not wild-type) enterocytes, revealing an unexpected opportunity for therapeutic intervention. Although APC-deficient cells show the expected increases in protein synthesis, our study reveals that it is translation elongation, and not initiation, which is the rate-limiting component. Mechanistically, mTORC1-mediated inhibition of eEF2 kinase is required for the proliferation of APC-deficient cells. Importantly, treatment of established APC-deficient adenomas with rapamycin (which can target eEF2 through the mTORC1–S6K–eEF2K axis) causes tumour cells to undergo growth arrest and differentiation. Taken together, our data suggest that inhibition of translation elongation using existing, clinically approved drugs, such as the rapalogs, would provide clear therapeutic benefit for patients at high risk of developing colorectal cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Lessons from hereditary colorectal cancer. Cell 87, 159–170 (1996)

  2. 2.

    et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science 275, 1784–1787 (1997)

  3. 3.

    et al. Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev. Cell 19, 259–269 (2010)

  4. 4.

    , , , & Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcΔ716 mice. Proc. Natl Acad. Sci. USA 105, 13544–13549 (2008)

  5. 5.

    et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin. Cancer Res. 15, 7207–7216 (2009)

  6. 6.

    et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc. Natl Acad. Sci. USA 110, 11988–11993 (2013)

  7. 7.

    et al. Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene 33, 1367–1374 (2014)

  8. 8.

    , & Rapamycin-insensitive regulation of 4E-BP1 in regenerating rat liver. J. Biol. Chem. 276, 10943–10951 (2001)

  9. 9.

    , & Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis 21, 469–476 (2000)

  10. 10.

    et al. Evidence for active Wnt signaling during postresection intestinal adaptation. J. Pediatr. Surg. 40, 1025–1029 (2005)

  11. 11.

    et al. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of β-catenin. Gastroenterology 126, 1236–1246 (2004)

  12. 12.

    et al. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol. Cell. Biol. 26, 8418–8426 (2006)

  13. 13.

    , & mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Rev. Mol. Cell Biol. 12, 21–35 (2011)

  14. 14.

    et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 486, 490–495 (2012)

  15. 15.

    , & Redundant sources of Wnt regulate intestinal stem cells and promote formation of Paneth cells. Gastroenterology 143, 1518–1529 (2012)

  16. 16.

    et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18, 39–51 (2010)

  17. 17.

    et al. Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche. Nature 459, 262–265 (2009)

  18. 18.

    , & Inhibition of translation in eukaryotic systems by harringtonine. Eur. J. Biochem. 72, 323–330 (1977)

  19. 19.

    et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nature Chem. Biol. 6, 209–217 (2010)

  20. 20.

    et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55–61 (2012)

  21. 21.

    & Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433, 477–480 (2005)

  22. 22.

    & A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol. Cell. Biol. 24, 2986–2997 (2004)

  23. 23.

    , & Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation. Nature 334, 170–173 (1988)

  24. 24.

    et al. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 16, 1017–1027 (2009)

  25. 25.

    et al. Cyclic AMP inhibits translation of cyclin D3 in T lymphocytes at the level of elongation by inducing eEF2-phosphorylation. Cell. Signal. 15, 871–881 (2003)

  26. 26.

    et al. An in vivo control map for the eukaryotic mRNA translation machinery. Mol. Syst. Biol. 9, 635 (2013)

  27. 27.

    et al. Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol. Cell 41, 419–431 (2011)

  28. 28.

    et al. Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int. J. Oncol. 34, 1181–1189 (2009)

  29. 29.

    et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142, 1504–1515 (2012)

  30. 30.

    et al. 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut 61, 1708–1715 (2012)

  31. 31.

    et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186–193 (2004)

  32. 32.

    et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003–1007 (2007)

  33. 33.

    et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278, 120–123 (1997)

  34. 34.

    , & A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322–324 (1990)

  35. 35.

    et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 14, 45–55 (2001)

  36. 36.

    et al. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab. 8, 399–410 (2008)

  37. 37.

    , , , & Faithful activation of an extra-bright red fluorescent protein in “knock-in” Cre-reporter mice ideally suited for lineage tracing studies. Eur. J. Immunol. 37, 43–53 (2007)

  38. 38.

    et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nature Med. 7, 1128–1132 (2001)

  39. 39.

    et al. The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J. Neurosci. 25, 9581–9590 (2005)

  40. 40.

    et al. Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17, 6649–6659 (1998)

  41. 41.

    Elongation factor-2 kinase and its newly discovered relatives. FEBS Lett. 514, 26–29 (2002)

  42. 42.

    et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 19, 2199–2211 (2005)

  43. 43.

    et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006)

  44. 44.

    , , , & mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468, 1100–1104 (2010)

Download references

Acknowledgements

W.J.F. is funded by AICR. O.J.S. is funded by Cancer Research UK, European Research Council Investigator Grant (COLONCAN) and the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement number 278568. M.B. is a Medical Research Council Senior Fellow. The authors acknowledge P. Cammareri, J. Morton and C. Murgia for proofreading of the manuscript.

Author information

Author notes

    • Thomas J. Jackson
    •  & John R. P. Knight

    These authors contributed equally to this work.

Affiliations

  1. Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK

    • William J. Faller
    • , Rachel A. Ridgway
    • , Thomas Jamieson
    • , Saadia A. Karim
    • , Sorina Radulescu
    • , David J. Huels
    • , Kevin B. Myant
    • , Helen A. Casey
    • , Alessandro Scopelliti
    • , Julia B. Cordero
    • , Marcos Vidal
    •  & Owen J. Sansom
  2. Medical Research Council Toxicology Unit, Leicester LE1 9HN, UK

    • Thomas J. Jackson
    • , John R. P. Knight
    • , Carolyn Jones
    • , Kate M. Dudek
    • , Martin Bushell
    •  & Anne E. Willis
  3. Institut Necker-Enfants Malades, CS 61431, Paris, France Institut National de la Santé et de la Recherche Médicale, U1151, F-75014 Paris, France Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France

    • Mario Pende
  4. Department of Pharmacology, Rutgers The State University of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA

    • Alexey G. Ryazanov
  5. Department of Biochemistry and Goodman Cancer Research Center, McGill University, Montreal, Québec H3A 1A3, Canada

    • Nahum Sonenberg
  6. Department of Biochemistry and Molecular Biology, IMRIC, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel

    • Oded Meyuhas
  7. Biozentrum, University of Basel, CH-4056 Basel, Switzerland

    • Michael N. Hall

Authors

  1. Search for William J. Faller in:

  2. Search for Thomas J. Jackson in:

  3. Search for John R. P. Knight in:

  4. Search for Rachel A. Ridgway in:

  5. Search for Thomas Jamieson in:

  6. Search for Saadia A. Karim in:

  7. Search for Carolyn Jones in:

  8. Search for Sorina Radulescu in:

  9. Search for David J. Huels in:

  10. Search for Kevin B. Myant in:

  11. Search for Kate M. Dudek in:

  12. Search for Helen A. Casey in:

  13. Search for Alessandro Scopelliti in:

  14. Search for Julia B. Cordero in:

  15. Search for Marcos Vidal in:

  16. Search for Mario Pende in:

  17. Search for Alexey G. Ryazanov in:

  18. Search for Nahum Sonenberg in:

  19. Search for Oded Meyuhas in:

  20. Search for Michael N. Hall in:

  21. Search for Martin Bushell in:

  22. Search for Anne E. Willis in:

  23. Search for Owen J. Sansom in:

Contributions

O.J.S., A.E.W. and W.J.F. designed the project. W.J.F., R.A.R., T.J. and S.R. performed breeding and phenotypic analysis of mice; W.J.F., T.J.J. and J.R.P.K. performed translational analysis; M.N.H., A.G.R., N.S., O.M., A.S., J.B.C., M.V., D.J.H., K.B.M., S.A.K., K.M.D., C.J., H.A.C. and M.P. provided advice and material; W.J.F., O.J.S., A.E.W. and M.B. wrote and edited the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Owen J. Sansom.

Extended data

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature13896

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.